Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis

Bone Marrow Transplantation volume 46, pages 557–561 (2011)Cite this article

Subjects

Abstract

Allogeneic haematopoietic stem-cell transplantation (HSCT) is the only curative treatment for myelofibrosis. We retrospectively analyzed the outcome of patients who underwent allogeneic HSCT, 1994–2008, and the potential risk factors affecting non-relapse mortality (NRM), OS and relapse-free survival (RFS). A total of 39 patients, 15–65 (median 49) years old, diagnosed with primary (n=27) or secondary (n=12) myelofibrosis underwent HSCT (25 related and 14 unrelated). In ten patients, disease had transformed into acute leukaemia. Lille prognosis score was low for 9, intermediate for 16 and high for 14 patients. The conditioning regimen was myeloablative (MAC) for 15 and reduced-intensity (RIC) fludarabine-based for 24, with successful engraftment in 38 patients. A total of 31 patients developed grade I–IV GvHD; 19 developed chronic GvHD. The 3-year OS, RFS and NRM rates (95% confidence interval) were 60% (42–74), 54% (37–59) and 30% (30–45), respectively.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A . Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61: 10–15.

    Article  CAS  PubMed  Google Scholar 

  2. Cervantes F, Villamor N, Esteve J, Montoto S, Rives S, Rozman C et al. ‘Lymphoid’ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol 1998; 100: 123–128.

    Article  CAS  PubMed  Google Scholar 

  3. Okamura T, Kinukawa N, Niho Y, Mizoguchi H . Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001; 73: 194–198.

    Article  CAS  PubMed  Google Scholar 

  4. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  PubMed  Google Scholar 

  5. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.

    Article  CAS  PubMed  Google Scholar 

  6. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A . Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973–977.

    Article  CAS  PubMed  Google Scholar 

  7. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831–2838.

    CAS  PubMed  Google Scholar 

  8. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355–365.

    Article  PubMed  Google Scholar 

  9. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065–3072.

    Article  CAS  PubMed  Google Scholar 

  10. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  11. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  12. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  14. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Prentice RL, Kalbfleisch JD, Peterson Jr AV, Flournoy N, Farewell VT, Breslow NE . The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554.

    Article  CAS  PubMed  Google Scholar 

  16. Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630–3636.

    CAS  PubMed  Google Scholar 

  17. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264–5270.

    Article  PubMed  Google Scholar 

  18. Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008; 93: 1514–1522.

    Article  CAS  PubMed  Google Scholar 

  19. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.

    Article  CAS  PubMed  Google Scholar 

  20. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.

    Article  CAS  PubMed  Google Scholar 

  21. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M . High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273–282.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Hématologie–Greffe, Saint-Louis Hospital, Université Paris 7-Diderot, Paris, France

    S Lissandre, R Peffault de Latour, G Socie & M Robin

  2. Service d'Hématologie, Hôtel-Dieu Hospital, Clermont-Ferrand, France

    J-O Bay, V Cacheux & A Cabrespine

  3. Service d'Hématologie, Michallon Hospital, Grenoble, France

    J-Y Cahn

  4. Département de Biostatistiques, Saint-Louis Hospital, Université Paris 7-Diderot, Paris, France

    R Porcher

  5. Service d'Hématologie, Institut de Cancérologie de la Loire, Saint Etienne, France

    J Cornillon

  6. Laboratoire de Biologie Cellulaire, Saint-Louis Hospital, Université Paris 7-Diderot, Paris, France

    B Cassinat

Authors
  1. S Lissandre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J-O Bay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-Y Cahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Porcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Cacheux
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Cabrespine
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Cornillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Cassinat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Peffault de Latour
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Socie
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Robin.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lissandre, S., Bay, JO., Cahn, JY. et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 46, 557–561 (2011). https://doi.org/10.1038/bmt.2010.276

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.276

Keywords

This article is cited by

Search

Advanced search

Quick links